Intrapatient Comparison of 111In-PSMA I&amp;T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer

Rauscher, Isabel; Maurer, Tobias; Souvatzoglou, Michael; Beer, Ambros J.; Vag, Tibor; Wirtz, Martina; Weirich, Gregor; Wester, Hans‐Juergen; Gschwend, Juergen E.; Schwaiger, Markus; Schottelius, Margret; Eiber, Matthias

doi:10.1097/rlu.0000000000001273

Cited by 45 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, especially in patients with biochemical relapse at low PSA values <1 ng ml −1 , the obtained detection rates of 99m Tc-labeled PSMA-SPECT/CT are lower than those reported by 68 Ga-PSMA PET/CT imaging 1. This is in line with our experiences in early recurrent prostate cancer patients and low PSA values investigated with PSMA tracers for SPECT/CT imaging 3. Although very useful for PSMA-radioguided surgery,45 111 In-labeled PSMA I&T (or 99m Tc-labeled PSMA I&S)-based SPECT/CT detects only less than half of the metastatic lesions that are identified by previous 68 Ga-PSMA PET/CT.…”

supporting

confidence: 88%

PSMA-targeted imaging of prostate cancer: evolution of a success story

Maurer

Eiber

2017

Asian J Androl

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 88%

PSMA-targeted imaging of prostate cancer: evolution of a success story

Maurer

Eiber

2017

Asian J Androl

Self Cite

View full text Add to dashboard Cite

“…Subsequently, in an evaluation of 99m Tc-MIP-1404 in 60 patients, the detection rates at PSA levels of greater than 2 ng/mL and less than or equal to 2 ng/mL were 91.4% and 40.0%, respectively (89). A direct comparison of 111 In-PSMA-I&T and 68 Ga-PSMA-11 in patients with early recurrence clearly showed a lower detection rate for 111 In-PSMA-I&T (90). Only 14 of 29 lesions with PET-positive results (48.3%) were visualized by 111 In-PSMA I&T.…”

Section: Psma Ligand Imaging Biochemical Recurrencementioning

confidence: 99%

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

et al. 2017

Self Cite

View full text Add to dashboard Cite

The prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer (PC) cells. Therefore, the targeting of PSMA has become increasingly important over the last decade. Glu-ureabased PSMA ligands used for both imaging and radioligand therapy are the mainstays of the current success. For PET imaging, both 68 Gaand 18 F-labeled agents have been successfully translated to clinical applications. Mainly retrospective cohort studies have shown a high value in the setting of biochemical recurrence, with high detection rates even in the presence of low prostate-specific antigen levels. Preliminary data indicated that radioguided surgery with PSMA ligands may help to further improve patient outcomes because it facilitates the removal of small tumor deposits that are otherwise difficult to detect. For primary PC, PSMA ligand PET imaging has been shown to be superior to cross-sectional imaging for the detection of metastatic lymph nodes. In addition, it promises to also provide intraprostatic tumor localization, especially when used in combination with multiparametric MRI. Increasing numbers of studies have reported considerable changes in management resulting from PSMA ligand PET imaging for both biochemical recurrence and primary disease. The use of 177 Lu-PSMA-based radioligand therapy has demonstrated a reasonable response, mainly as defined by a prostate-specific antigen response of more than 50%, comparable to other recently introduced agents. Especially given the high level of safety of 177 Lu-PSMA radioligand therapy, with only minimal grade 3 and 4 toxicities reported so far, it has the potential to expand options for metastatic castrationresistant PC. This review is intended to provide a comprehensive overview of the current literature on low-molecular-weight PSMA ligands for both PET imaging and therapeutic approaches, with a focus on agents that have been clinically adopted.

show abstract

“…Of 18 DOTA conjugates with optimized linker moieties between the Glu-urea-Lys-binding motif and the DOTA chelator, PSMA-617 was identified as the best candidate for translation to clinical settings (20,21). In parallel, another theranostic PSMA radioligand, PSMA for imaging and therapy (PSMA I&T), was also described (22,23). 177 Lu-PSMA-617 and the 225 Ac-labeled version are currently the main candidates for endoradiotherapy (i.e., PSMA RLT) of PC (24)(25)(26)(27).…”

mentioning

confidence: 99%

“…68 Ga-PSMA-11, 18 F-DCFBC, 18 F-DCFPyL, and 18 F-PSMA-1007 are exclusive PET PSMA radioligands. PSMA-617 and PSMA I&T are theranostic PSMA radioligands because they can be radiolabeled with both diagnostic (e.g., 68 Ga and 44 Sc) and therapeutic (e.g., 177 Lu) radiometals (23,39,40). Because PSMA-1007 is derived from PSMA-617, the tracers ( 18 F-PSMA-1007 and 177 Lu-PSMA-617) can be used as a theranostic tandem of PSMA radioligands.…”

mentioning

confidence: 99%